

# TRICARE Prior Authorization Request Form for (crizotinib) Xalkori capsules, pellets



**JOHNS HOPKINS**  
HEALTH PLANS

7231 Parkway Drive, Suite 100, Hanover, MD 21076

**FAX Completed Form and  
Applicable Progress Notes to:  
(410) 424-4037**

## USFHP Pharmacy Prior Authorization Form

To be completed by Requesting provider	
Drug Name:	Strength:
Dosage/Frequency (SIG):	Duration of Therapy:

**Questions?** Contact the Pharmacy Dept at: (888) 819-1043, option 4

**Clinical Documentation must accompany form in order for a determination to be made.**

Prior authorization does not expire.

For patients UNDER 12 years of age, no prior authorization is required.

**Step 1 Please complete patient and physician information (please print):**

<b>1</b>	Patient Name: _____	Physician Name: _____
	Address: _____	Address: _____
	Sponsor ID #: _____	Phone #: _____
	Date of Birth: _____	Secure Fax #: _____

**Step 2 Please complete the clinical assessment:**

<b>2</b>	1. Is the request medication being prescribed by or in consultation with a hematologist/oncologist?	<input type="checkbox"/> Yes Proceed to question 2	<input type="checkbox"/> No <b>STOP</b> Coverage not approved
	2. What is the indication or diagnosis?	<input type="checkbox"/> Metastatic non-small cell lung cancer (NSCLC) - Proceed to question 3 <input type="checkbox"/> Relapsed or refractory systemic anaplastic large cell lymphoma (ALK) positive - Proceed to question 4 <input type="checkbox"/> Unresectable, recurrent, or refractory inflammatory myofibroblastic tumor – Proceed to question 5 <input type="checkbox"/> Other - Proceed to question 7	
	3. Is the NSCLC tumor anaplastic lymphoma kinase (ALK) positive or ROS1-positive (as detected by an FDA-approved test)?	<input type="checkbox"/> Yes Proceed to question 10	<input type="checkbox"/> No <b>STOP</b> Coverage not approved
	4. Is the patient 1 year of age and older or a young adult? <small>(Note – limitation of use: safety and efficacy of Xalkori have not been established in older adults with relapsed or refractory systemic ALK-positive anaplastic large cell lymphoma)</small>	<input type="checkbox"/> Yes Proceed to question 10	<input type="checkbox"/> No <b>STOP</b> Coverage not approved
	5. Is the patient greater than or equal to 1 year(s) of age?	<input type="checkbox"/> Yes Proceed to question 6	<input type="checkbox"/> No <b>STOP</b> Coverage not approved

# TRICARE Prior Authorization Request Form for (crizotinib) Xalkori capsules, pellets

<b>6. Is the tumor anaplastic lymphoma kinase (ALK)-positive?</b>	<input type="checkbox"/> Yes Proceed to question <b>10</b>	<input type="checkbox"/> No <b>STOP</b> Coverage not approved
<b>7. Please provide the diagnosis.</b>	<hr style="width: 50%; margin: auto;"/> Proceed to question <b>8</b>	
<b>8. Is the diagnosis cited in the National Comprehensive Cancer Network (NCCN) guidelines as a category 1, 2A, or 2B recommendation?</b>	<input type="checkbox"/> Yes Proceed to question <b>10</b>	<input type="checkbox"/> No <b>STOP</b> Coverage not approved
<b>9. What is the requested medication?</b>	<input type="checkbox"/> crizotinib (Xalkori) oral pellets - Proceed to question <b>10</b> <input type="checkbox"/> crizotinib (Xalkori) capsules - <b>Sign and date below</b>	
<b>10. Please explain why the patient requires Xalkori oral pellets and cannot take Xalkori capsules.</b>	<hr style="width: 50%; margin: auto;"/> <b>Sign and date below</b>	

**Step 3** I certify the above is true to the best of my knowledge.  
Please sign and date:

\_\_\_\_\_

Prescriber Signature

\_\_\_\_\_

Date

[08 May 2024]

For Internal Use Only	
<input type="checkbox"/> Approved:	Duration of Approval: ____ month(s)
<input type="checkbox"/> Denied:	Authorized By:
<input type="checkbox"/> Incomplete/Other:	PA#:
Date Faxed to MD:	Date Decision Rendered: